GKOS · GLAUKOS Corp
$189.55
+5.40 (+2.93%)
At close · Aug 19
Market Cap
$11.18B
Shares
58.98M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$189.55
Open$186.00
Day$185.96–190.06
52W close$74.67–189.55
Avg vol 30d815K
Short int3.6M · 6.1% float · 3.6d
Short vol48%
Last earningsJul 29, 2026
DataJan 2020–Aug 2026
Filing10-Q · Jul 29
Up next
Next earnings call
Oct 28, 2026
Est · unconfirmed
· in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Jul 29, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+53%
above
Price vs 50-day avg
+23%
above
RSI (14)
76
overbought
MACD trend
Positive
52-week position
100%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+24%
trailing
6-month return
+56%
trailing
YTD return
+68%
this year
Relative strength
+45%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $154 › 200d $124 — 50d above 200d
Institutional flow
Accumulating
+7% holders QoQ · +68 funds added
Insider flow
Distributing
Net -$10.9M over 90 days · 100% sells
Short interest
Falling
6.15% of float · ▼ -22.9% MoM · 3.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
364 holders — near 3-yr high, broad support
Squeeze score
60
elevated · 0–100
Fundamentals
Revenue growth
+32%
Y/Y
Gross margin
56%
contracting
EPS growth
−18%
Y/Y
Free cash flow
$-22.5M
Balance sheet
$81.1M
net cash
Quant / Vol
risk profile
Volatility
53%
annualized · 1-yr
Max drawdown
−28%
past year
ATR
3.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Jul 29, 2026
2026 net sales
· 2026
$680M – $700M
prior FY $507.44M
midpoint +36.0% Y/Y
Prior guidance
period ended
· from the Earnings Call filed Sep 30, 2025
Net sales
· full year 2025
$490M – $495M
Guided vs delivered
· last 2 settled
Full-year 2024 net sales
full-year 2024
guided $350M – $360M
$383.48M
Beat +8.0%
2023 net sales guidance range
2023
guided $307M – $310M
$314.71M
Beat +2.0%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+53%
Bullish
Price vs 50-day avg
+23%
Bullish
RSI (14)
76
Bearish
MACD trend
Positive
Bullish
52-week position
100%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $154 › 200d $124 — 50d above 200d
Institutional flow
Accumulating
+7% holders QoQ · +68 funds added
Insider flow
Distributing
Net -$10.9M over 90 days · 100% sells
Short interest
Falling
6.15% of float · ▼ -22.9% MoM · 3.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
364 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $75
Now $190 · 100%
Range high $190
vs 200-day avg +53%
vs 50-day avg +23%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Gross margin | 82% | the second quarter of 2026 | — |
| International Glaucoma Reported Sales | 36.63M | Q2 2026 | — |
| International Glaucoma Year-over-Year Operations Percent Change | 16.4% | Q2 2026 | — |
| International Glaucoma Year-over-Year Reported Percent Change | 17.2% | Q2 2026 | — |
| non-GAAP Cost of sales non-GAAP | 28.74M | Q2 2026 | — |
| Non-GAAP gross margin non-GAAP | 85% | the second quarter of 2026 | — |
|
|
|||
| Non-GAAP loss from operations non-GAAP | $7.6M | the second quarter of 2026 | — |
|
|
|||
| Non-GAAP net loss per diluted share non-GAAP | -$0.14 | the second quarter of 2026 | — |
| Non-GAAP SG&A expenses non-GAAP | $111.7M | the second quarter of 2026 | — |
|
|
|||
| Total Net Sales Year-over-Year Operations Percent Change | 49.3% | Q2 2026 | — |
| non-GAAP net loss non-GAAP | $10.4M | first quarter of 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net loss -19.78M
+9.37M Adjustments (including total tax effect for non-GAAP pre-tax adjustments)
= Non-GAAP Net loss -10.42M
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GKOS
this stock
GLAUKOS Corp
|
$11.18B | +67.9% | +32.3% | — | 6.1% |
|
ABT
Abbott Laboratories
|
$196.27B | -8.7% | +5.7% | 31.6 | 1.3% |
|
SYK
Stryker Corp
|
$127.34B | -3.3% | +11.2% | 34.4 | 2.2% |
|
MDT
Medtronic plc
|
$115.97B | -2.0% | +8.4% | 24.3 | 1.4% |
|
BSX
Boston Scientific Corp
|
$73.14B | -45.5% | +12.5% | 20.4 | 1.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GKOS | +1.6% | +24.0% | +56.1% | +13.7% | +67.9% |
| SPY | -0.4% | +2.9% | +11.6% | +3.0% | +12.8% |
| vs SPY | +2.0% | +21.1% | +44.5% | +10.7% | +55.1% |
Key facts
CIK
1192448
CUSIP
377322102
13F (30d)
328 filings
325 filers
Visit website
Investor relations